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Serotonin (5-hydroxytyramine) is a mediator of gastrointestinal smooth muscle contraction, and 
is secreted by neuroendocrine neoplasms (NENs). We developed a liquid chromatography 
tandem mass spectrometry (LC-MS/MS) assay for serum serotonin to be used in NEN 
diagnostics and follow-up. 
Methods 
We used serum samples from healthy volunteers (n=31) and patients suspected or monitored 
for NEN (n=98). Serotonin-D4 internal standard was added to samples before solid phase 
extraction (SPE) and quantification by LC-MS/MS. The effects of sample handling and 
preparation on serotonin stability were studied. Finally, we established a provisional reference 
range for serum serotonin and compared our assay with serum 5-hydroxyindoleacetic acid (5-
HIAA) for detection of NENs. 
Results 
Our assay is sensitive and has a wide linear range (10-10000 nmol/l). Serum serotonin is stable 
for 7 days at room temperature and for 3 months at -20 ºC. Sampling temperature is not critical. 
Normal range for serum serotonin was 270-1490 nmol/l. We found that serum serotonin and 5-
HIAA performed equally well as diagnostic tests for NENs. 
Conclusions 
Our LC-MS/MS assay for serum serotonin is well suited for clinical research and patient 
diagnostics. Our results confirm that it can complement 5-HIAA in diagnosis of NENs.  
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Serotonin (5-hydroxytryptamine) is a monoamine neurotransmitter synthesized from the amino 
acid tryptophan. Most of total body serotonin is found in the gastrointestinal (GI) tract, where it 
modulates the functions of the bowel by controlling smooth muscle contraction. It also acts as a 
cardiovascular vasoconstriction mediator and in the brain as a neurotransmitter. Any 
irregularities in the serotonergic system may thus contribute to various clinical conditions such 
as bowel motility disorders, cardiac abnormalities, and negative effects on the mood and 
memory regulation [1].  
Neuroendocrine neoplasms (NENs), which originate from GI tract enterochromaffin cells, may 
produce large amounts of serotonin. Tumors of the fore- and midgut produce predominantly 
serotonin, while production is usually minimal in tumors of the hindgut. The incidence of NEN is 
relatively low, 5:100000, but diagnoses are becoming more common [2], primarily due to 
improvements in early detection of the disease. NENs occur in all age groups, but are the most 
common in patients aged 60-70 years. Traditionally, the diagnosis of these tumors is based on 
symptoms, detection of serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) [3] and 
chromogranin A (CgA) [4], and imaging results. Some studies have proposed platelet, plasma or 
urinary serotonin assays to complement these [5,6] due to their high sensitivity in detecting 
especially serotonin producing midgut tumors. 
Previous assays for serotonin are immunoassays or based on liquid chromatography with 
fluorometric [7], electrochemical (EC) [8] or mass spectrometric detection [9,10]. Many 
previously published methods employ platelet poor plasma, where serotonin concentration is 
low and sample handling may be laborious and prone to errors [6,8,11-13]. As platelets readily 
store serotonin via an active uptake process, serotonin concentration in regular serum is 
significantly higher and sample handling and preparation more straightforward. Plasma 
serotonin concentration has also been found to be affected by dietary intake of serotonin-rich 
foods while serum serotonin is not [14].  
We have previously used a serum 5-HIAA assay for NEN diagnostics [3]. To complement our 
earlier work, we developed a new LC-MS/MS assay for serum serotonin and evaluated the 
discriminating power of serotonin as a NEN marker as compared to our previous serum 5-HIAA 
test. Some diagnostic laboratories [15] suggest cold sampling procedures for serotonin. 
Therefore, we also wanted to investigate, whether cold sampling procedure is necessary and 
studied preanalytical factors such as sample stability and sampling device. 
2. Materials and methods 












Stock solutions of 10 µmol/l (1.76 mg/l) serotonin (Sigma-Aldrich Co) in 1% acetic acid (174 
mmol/l) and deuterium labeled serotonin-D4 internal standard (IS) (Medical isotopes Inc. 
Pelham, NH, USA) in water were prepared. Serotonin calibrators in water (0.06-10000 nmol/l) 
and IS working solution (1000 nmol/l) in 20 mmol/l ammonium acetate were freshly prepared 
from the stock solutions. Sample pretreatment was performed employing 96-well Oasis WCX 
µElution plates (Waters, Milford, MA, USA). MS-grade methanol, acetonitrile (ACN), formic acid, 
acetic acid and ammonium formate were from Fluka (Sigma-Aldrich Co.). All reagents were of 
the highest analytical grade. 
 
2.2. Samples and patients 
Serum and plasma samples from apparently healthy volunteers were obtained in May 2016 
from our laboratory staff (30 women and 6 men) with a median age of 48 yrs (range 27-65 yrs). 
Informed consent was obtained from all individuals. The samples were kept at -20 °C until 
analysis unless otherwise stated. Patient samples (50 women, 48 men) were from individuals 
suspected or followed for active NEN (assessed by clinical examination, other blood tests, 
including CgA and 5-HIAA and radiological studies) at the Endocrine Department and from 
whom serum samples were drawn and analyzed for 5-HIAA during 2016 as part of their 
diagnostic work-up as previously described [3] (Table 1). Most patients (ca. 70%) had been 
diagnosed at some point with a tumor of the ileum, the rest were divided among other midgut 
tumors (2%), foregut tumors (15%), non-GI tumors (4%) and unconfirmed tumor (9%). This 
study was approved by the ethical committee of Helsinki University Central Hospital, Finland. 
 
2.3. Sample and calibrator preparation 
Samples and calibrators (100 µl) were pipetted into the wells of a 96-well plate along with 100 µl 
of IS working solution. A sample volume of 200 µl was used for platelet poor plasma (PPP). 
WCX µElution plate was wetted with 200 µl of methanol and 200 µl of water. Samples and 
standards including the IS were transferred into the µElution wells followed by washing with 200 
µl of 20 mmol/l ammonium acetate and 200 µl of methanol. Serotonin was then eluted with 100 
µl of methanol/formic acid/ water (30/5/65, v/v) and analyzed by liquid chromatography tandem 
mass spectrometry (LC-MS/MS).  
 
2.4. LC–MS/MS 
The system comprised an Agilent 1200 liquid chromatograph (Agilent Technologies, Santa 












Canada) equipped with a Turbo-V electrospray ion (ESI) source. For separation, Atlantis HILIC 
Silica 50 x 2.10 mm 3 µm column (Waters) was used and operated at 40 °C. Elution buffers 
were ACN (A) and 90 mmol/l ammonium formate, pH 4 (B). The column was kept at 5% B for 
0.5 min, ramped from 5% to 50% B in 0.5 min, from 50% to 5% B in 0.6 min and kept at 5% B 
for 6.4 min. The flow rate was 300 µl/min. For MS/MS detection transitions m/z 177 → 115 and 
m/z 181 → 164.2 for serotonin and the IS were followed, respectively. The ion source was kept 
at 5000 V and at 600 °C in positive ion mode. Settings for the curtain, nebulizer and heater 
gases were 20, 60 and 50 l/min, while the collision gas setting was at 9. Data was collected and 
processed by the Analyst software (Version 1.6.2, AB Sciex). 
 
2.5. Analytical validation of the method 
The linearity was determined by preparing and analyzing 15 calibrator dilutions (0.625-10000 
nmol/l) on three different days. The calibration curve was derived using 1/x2 weighted linear 
least-squares regression. Relative error (RE%) and the coefficient of variation (CV%) were 
calculated to assess accuracy and precision, respectively. The limit of detection (LOD) was 
determined as the lowest concentration with a signal to noise ratio of 3. Limit of quantification 
(LOQ) and linear range was determined as the lowest concentration and range, respectively, 
that could be measured with RE and CV <20%. For quality assurance (QA), we employed 
Clinchek level 1 and 2 Plasma Controls for biogenic amines (RECIPE, Munich, Germany) 
containing 590 and 1700 nmol/l serotonin, respectively. Intra- and inter-assay variation were 
calculated from the QA sample results in a single batch (n=12) and on 14 separate days, 
respectively. Recovery of added serotonin was determined using three serum samples 
(endogenous serotonin concentration 207-803 nmol/l) with and without serotonin spike of 250 
and 1000 nmol/l. Matrix effect was studied by extracting two serum samples in triplicate, spiking 
with 250 nmol/l of serotonin after sample extraction and comparing with spiked elution buffer. 
Effect (attenuation or enhancement) on the measured signal was calculated from the peak 
areas. 
 
2.6. Preanalytical validation 
We studied sample stability using fresh serum samples (n=15) from healthy individuals 
aliquoted at room temperature, +4 °C and -20 °C. The non-frozen samples were analyzed on 
days 0, 1, 2, 3, 4 and 7. The frozen samples were analyzed on days 0, 7, 21, 28, 42, 56, 84 and 
180. The effect of repeated freezing and thawing from the same aliquot was studied on the 












The effect of sampling device was studied with blood samples collected from 31 healthy 
volunteers. Samples were drawn into plain serum tubes, serum activator tubes (CAT), serum 
gel tubes (SSTTM II Advance, all from BD Vacutainer, Plymouth, UK) and lithium-heparin tubes 
(Venosafe 60 USP U Lithium Heparin, Terumo, Leuvon, Belgium). Separation of serum or 
plasma was performed as suggested by the respective manufacturer and analyzed immediately. 
Suggested minimum clotting time for serum was 30 min (actual 60 min). Plasma samples were 
separated in 15 min. 
Delayed (up to 6 hrs) centrifugation after sampling (n=6) on serotonin concentration was studied 
using plain serum tubes. The effect of sampling temperature was tested with duplicate samples 
(n=11) kept either at room temperature or +4 °C through the entire sampling and preanalytical 
process. 
For preparation of platelet poor plasma (PPP, n=12), samples from healthy individuals were 
drawn into citrate plasma tubes (BD Vacutainer). After 15 minutes, the samples were 
centrifuged at 3000 g for 10 min, the top 2/3 of plasma collected and re-centrifuged.  
 
2.7. Serum 5-HIAA assay 
Serum 5-HIAA was analyzed as previously described [3]. Briefly, serum samples were extracted 
using Oasis WAX µElution plates by washing with 2% formic acid and 60% ACN and then 
eluting with the LC buffer (97% A, 3% B, same eluents used as in here). The MS transitions 
were m/z 192.1 → 146 for 5-HIAA and m/z 194 → 147.9 for IS. 
 
2.8. Statistical methods 
We used Analyse-it for Microsoft Excel 2016 (Ver. 4, Analyse-it software Ltd, 
http://www.analyse-it.com) to establish a provisional reference range for serum serotonin by a 
parametric method, to run receiver operating characteristic (ROC) analysis, Deming regression 
and paired t-tests. A p-value <0.05 was considered statistically significant. 
 
3. Results 
3.1. Analytical validation of the serotonin assay 
The retention time of serotonin and IS was 3.27 min (Figure 1). The method was linear over the 
concentration range 10-10000 nmol/l, the LOD was 2.5 nmol/l and LOQ 10 nmol/l. Routinely, we 
used 10-5000 nmol/l calibrators. The intra-assay CVs were 3.5% and 5.4% and the interassay 
CVs 5.2% and 7.8% at 590 and 1700 nmol/l serotonin, respectively. The mean recoveries of 












endogenous serotonin were 102% (range 95-115%) and 101% (range 97-109%), respectively. 
Sample matrix suppressed the measured serotonin and IS signal by 26%. 
 
3.2. Preanalytical validation 
There was no difference in serotonin concentrations in samples drawn into serum activator 
(mean 843, range 407-2060 nmol/l) or gel tubes (mean 855, range 398-2060 nmol/l). However, 
serotonin concentrations were lower in samples drawn into plain serum tubes (mean 707, range 
262-1550 nmol/l, p=0.0001), into lithium-heparin tubes (mean 48, range 33-89 nmol/l, p<0.0001) 
and in PPP (mean 11, range 5-30 nmol/l, p=0.0005) (Figure 2). In this study we used samples 
drawn into plain serum tubes unless otherwise stated. 
The measured mean serum serotonin concentration was 15% (797 nmol/l, p=0.0327) and 20% 
(767 nmol/l, p=0.0187) lower than the initial 958 nmol/l after a delay of 4 hrs and 6 hrs before 
centrifugation, respectively. There was no difference observed between 1 and 2 hrs delay time. 
Cooled sampling during the preanalytical phase was not critical (p=0.8855, Figure 3). 
Serum serotonin was stable for at least seven days at room temperature (mean 631-711 nmol/l) 
and +4 °C (mean 645-713 nmol/l), for 84 days at -20 °C (mean 629-711 nmol/l) and for seven 
freeze-thaw cycles (mean 621-711 nmol/l) (Figure 4). 
 
3.3. Serum serotonin and 5-HIAA concentrations 
Mean serum serotonin and 5-HIAA concentrations in healthy individuals was 632 nmol/l (range 
262-1550 nmol/l) and 67 nmol/l (range 30-140 nmol/l), respectively. The upper reference limit of 
our serum 5-HIAA assay is 123 nmol/l [3]. We suggest a provisional reference range of 270-
1490 nmol/l for serum serotonin (95% confidence intervals 210-342 nmol/l and 1170-1900 
nmol/l for lower and upper limits, respectively) (Figure 5). In our study, genders did not differ 
significantly (p=0.661) in serum serotonin content. 
In patient samples, serum serotonin concentration was 42-13200 nmol/l (mean 1833 nmol/l) and 
that of 5-HIAA was 23-3170 nmol/l (mean 366 nmol/l). On average, serum serotonin 
concentration was 5-fold compared to serum 5-HIAA. Serum serotonin and 5-HIAA 
concentrations of all samples correlated according to y (serotonin, nmol/l) = 398.4 + 3.919 x (5-
HIAA, nmol/l) by Deming regression (Sy|x=2663, n=128). Four of 39 active NEN patients had no 
elevation in either analyte concentration, among them one patient had a non-GI tumor, one with 
pancreatic tumor and two with ileum tumors. Two patients with midgut tumors (ileum) had 
elevated serotonin only. Finally, six patients had elevated 5-HIAA but normal serotonin 












remaining NEN samples (n=27) the concentration of both analytes was elevated above the 
upper reference limit. In ROC analysis, the areas under curve (AUC) for serotonin and 5-HIAA 
were 0.91 and 0.94, respectively (Table 2). With cut-off values of 1490 nmol/l for serotonin and 




There are few extensively validated LC-MS/MS-based serotonin assays in literature. The LOQ 
for our new serotonin LC-MS/MS assay was 10 nmol/l and the linear range is 10-10000 nmol/l. 
A better sensitivity can be achieved by using 200 µl sample volume instead of 100 µl as we 
used for PPP samples with <10 nmol/l serotonin. Previously described serotonin assays have 
LOQ of 1-50 nmol/l and linear range of 3.5-5000 nmol/l [9,10,16-18]. Our assay compares 
favorably with these with inter- and intra-assay CVs of <10 %.  
Methods based on immunoassays and HPLC paired with fluorescence, UV or electrochemical 
detection may be laborious and suffer from interference from related compounds present in 
samples. MS based detection has excellent specificity and sensitivity for clinical applications. 
Sample treatment of our assay relies on SPE, while others have reported a simple precipitation 
step sufficient [17]. Time-consuming derivatization procedures like that in [19] are not required. 
In this study, serum serotonin was stable at -20 °C for 84 days and during 5 freeze-thaw cycles. 
Serotonin was stable for one week when stored at +4 °C and at room temperature, provided that 
the samples had been initially centrifuged within two hours. These results confirm those of 
previous reports [10,20]. Therefore, serum samples can be handled and transferred at room 
temperature, which is an advantage for today’s centralized clinical laboratories. 
We found that plain serum tubes yielded slightly lower serotonin concentrations when compared 
to gel or clotting activator tubes. Clotting is known to release serotonin from platelets [21]. This 
finding suggests that this process is more efficient in gel and in clotting activator tubes than in 
plain serum tubes. Plasma samples drawn to lithium-heparin tubes produced markedly lower 
results, while PPP samples drawn sodium citrate tubes were the lowest in serotonin 
concentration, due to smaller platelet amount in PPP. For serum assay, any of the tested 
sampling devices can be used, but the reference values need to be established for each 
sampling device. We used samples drawn into plain serum tubes in this study. 
Previously reported LC-MS/MS methods have widely used platelet rich plasma (PRP), PPP or 
urine as the sample matrix. When preparing PRP or PPP for serotonin analysis, careful sample 












serotonin concentrations vary widely between studies, i.e. from 0.6 to 180 nmol/l [13], although 
the few MS-based assays report levels of 1-5 nmol/l. This discrepancy is probably due to 
differences in plasma treatment procedures, resulting in varying amounts of platelets present, 
as well as different analytical techniques. Our PPP serotonin results (mean 10.7, range 5.3-29.9 
nmol/l, n=12) are similar to those reported by de Jong et. al.[9] using an LC-MS/MS assay 
(mean 4.6 nmol/l, range 2-15 nmol/l, n=22). Our samples drawn into lithium-heparin tubes 
produced higher results as expected. These samples were not doubly centrifuged and thus they 
were likely to contain platelets. 
We found that serum serotonin concentration decreased upon delayed (4 and 6 hrs) sample 
centrifugation (mean concentration 797 and 767 nmol/l) compared to standard separation 
(mean 957 nmol/l, p=<0.033, n=11). In the body, serotonin is degraded by the enzyme 
monoamine oxidase (MAO [6]) and in circulation the half-life of serotonin is 1.3 hrs [22]. MAO 
activity may cause serotonin degradation also in vitro, but in this study the mechanism was not 
elucidated. There was no difference in serotonin concentrations between cold sampling and 
treatment (mean 1018 nmol/l) as compared to handling at room temperature (mean 1004 nmol/l, 
p=0.9157). Taken together, our limited study suggests that sampling temperature is not critical, 
but a delay of 4 hrs or more between sampling and sample centrifugation may affect serotonin 
concentration in the sample.  
A previous study suggest that gender does not influence circulating levels of serotonin [23]. 
Likewise, we found no statistical difference between the genders. Therefore, we established an 
upper 95% provisional reference limit of 1490 nmol/l for serum serotonin in adults (combined 
gender). This result is in line with other studies. Korse et al. [10] suggest an upper limit of 1356 
nmol/l using LC-MS/MS assay detection, while methods based on fluorescence or EC report 
concentrations of ca. 1200-2000 nmol/l (given as 5.1-7.8 nmol/109 platelets) [7,11,24,25]. 
Comparison of serotonin concentrations in serum samples from healthy volunteers and NEN 
patients either in remission or with an active disease showed a clear difference between the 
groups. Patients with confirmed active NEN had significantly elevated serum serotonin levels, 
while in samples from patients in remission it differed only slightly from that in healthy 
volunteers. When we compared serum serotonin and serum 5-HIAA assay by ROC analysis 
(Table 2), both methods discriminated equally well between healthy subjects and patients with 
active disease with AUCs 0.91 and 0.94, respectively. Our findings are in accordance with those 
of Meijer et al. (19). In their study, platelet serotonin (AUC 0.89) was slightly better at 
discriminating carsinoid patients from the healthy as compared to urinary serotonin (AUC 0.84) 












NENs of the midgut, while 5-HIAA was slightly better as a foregut tumor marker. This is also in 
line with other studies [5,26], and is linked to the different serotonin secretion rates between 
tumors of the fore- and midgut, as well as their varying enzymatic synthesis rate from 
tryptophan to serotonin.  
In conclusion, our new LC-MS/MS assay for serum serotonin suits well for routine clinical 
laboratories for NEN diagnostic and for research purposes. The linear range covers a wide 
physiological range including both normal subjects and NEN patients’ serotonin concentrations. 
Serum samples are stable for several days at room temperature or months when frozen. The 
established provisional cut-off-value of 1490 nmol/l discriminates well between healthy 
individuals and patients with active NENs. Further studies to confirm the clinical utility of serum 
serotonin in NEN diagnostics are warranted. 
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Figure 1. Chromatograms of a serotonin calibrator (A), of a serum sample from a healthy 
individual (B) and from a NET patient (C) with 500, 605 and 8100 nmol/l of serotonin, 
respectively. 
Figure 2. Distribution of serotonin concentrations in samples drawn into plain serum (serum), 
serum activator (CAT), serum gel and plasma (Li-heparin) tubes from 31 healthy donors.  
Figure 3. Effect of sample handling temperature on serotonin concentration on parallel samples 
(n=11). 
Figure 4. Mean (±SD) serum serotonin stability of samples (n=15) drawn into plain serum tubes 
at -20 °C. 
Figure 5. Serotonin (A) and 5-HIAA (B) concentrations in serum from healthy individuals (No 
NEN, n=89) and from active NEN patients (n=39). The dotted line shows the respective upper 












Table 1. Details of the NEN patients. 
Information Mean (range) 
Age, years 63.8 (26-86) 
Sex, M/F 48/50 
Diagnosis  
In remission 58 
Time from diagnosis, years 4.2 (0-13) 
Active NEN 39 
Time from diagnosis, years 3.7 (0-12) 
Tumor location  
Foregut 14 
Lungs / Liver / Pancreas 4/1/9 
Midgut 70 
Ileum / Appendix 68/2 
Other 4 













Table 2. AUC, sensitivity and specificity of serum serotonin and serum 5-HIAA assays. Cut-off 
values were 1490 nmol/l and 123 nmol/l for serum serotonin and 5-HIAA, respectively. 
 
 




AUC 0.91 0.94 
Sensitivity (%) 75 85 
Specificity (%) 92 85 
Remission/Active NEN (n) 58/39 58/39 
AUC 0.90 0.93 
Sensitivity (%) 75 85 
Specificity (%) 90 83 
Healthy/Active NEN (n) 31/39 31/39 
AUC 0.91 0.95 
Sensitivity (%) 75 85 
















































































 A new LC-MS/MS assay for serum and plasma serotonin was developed 
 Analytical performance was good and assay covered relevant clinical concentrations 
 Sampling and stability were studied and found suitable for clinical laboratory 
 Serum serotonin can be used to discriminate the healthy from the NEN patients 
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